國(guó)際新聞精選周四（2017年2月23日）

2017年2月23日 | Filed under: | Posted by: 編輯 D

Cancer startup PMV Pharma gains impressive $74M B round

New Jersey oncology biotech PMV Pharma has seen a healthy $74 million in funding from its Series B with help from InterWest Partners, Osage University Partners, Topspin Biotech Fund (which led this round), and its Series A lead investor OrbiMed.

The company said it will use its new cash boost for work on its p53-targeted small molecule drugs in cancer, building on the $30 million it got back in December 2014.【閱讀原文】

2016 went out like a lamb in the biopharma M&A world. Will it roar back in 2017? Plus, top 10 deals

Dealmakers evidently spent the fourth quarter of 2016 largely in hibernation as they waited out a big US election cycle that seemed to raise more questions than it answered.

In a look back over a relatively quiet year, EP Vantage, the editorial arm at Evaluate, concluded that 2016 may not have ended anywhere close to any of the records set during the boom, but I would add that the numbers reflect some considerable financial muscle that could be flexed in the year to come.【閱讀原文】

Oncternal Closes $18.4 Million Series B Financing

Oncternal Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class therapies for both rare and common malignancies, today announced the closing of an $18.4 million Series B financing. The company intends to use the proceeds to further clinical development programs for cirmtuzumab and TK216, and to advance preclinical development of a new ROR1-targeted antibody-drug conjugate (ADC) program.【閱讀原文】

Argos kidney cancer vax fails phase 3 futility review, future in doubt

Argos Therapeutics’ hopes of winning approval for its cancer vaccine candidate rocapuldencel-T have taken a major blow. The independent monitoring committee recommended the phase 3 trial is stopped for futility after getting a look at interim results, wiping 65% off Argos' stock and leaving it to scour through the data in search of a path forward for its lead candidate.【閱讀原文】

Icon to validate PROs as measurement of clinical endpoints for the FDA

The U.S. FDA has selected Icon to validate three patient-reported outcome (PRO) instruments used to assess clinical endpoints in antibacterial drug trials.

With the help of the Biomarkers Consortium of the Foundation for the National Institutes of Health, Icon’s Clinical Outcomes Assessment group will develop an electronic platform to validate PROs.【閱讀原文】

Scientists identify chain reaction that shields breast cancer stem cells from chemotherapy

Working with human breast cancer cells and mice, researchers at Johns Hopkins say they have identified a biochemical pathway that triggers the regrowth of breast cancer stem cells after chemotherapy.

The regrowth of cancer stem cells is responsible for the drug resistance that develops in many breast tumors and the reason that for many patients, the benefits of chemo are short-lived. Cancer recurrence after chemotherapy is frequently fatal.【閱讀原文】

Icahn has snapped up a Bristol-Myers stake. Could megamerger pressure be far behind?

What a difference one failed trial makes. After Bristol-Myers Squibb’s immunotherapy Opdivo fell short in a key lung cancer study last fall, the company’s shares plummeted, analysts cut their sales forecasts by billions, and buyout rumors started surfacing.

Now, activist investors are plowing in.【閱讀原文】

美中藥源原創(chuàng)文章，轉(zhuǎn)載注明出處并添加超鏈接，商業(yè)用途需經(jīng)書面授權(quán)。
★更多深度解析訪問《美中藥源》~

★ 請(qǐng)關(guān)注《美中藥源》微信公眾號(hào) ★